300497 Stock Overview
Engages in the research, development, manufacture, and sale of APIs and pharmaceutical intermediates in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Jiangxi Fushine Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.34 |
| 52 Week High | CN¥13.24 |
| 52 Week Low | CN¥5.62 |
| Beta | 0.37 |
| 11 Month Change | 21.22% |
| 3 Month Change | 39.12% |
| 1 Year Change | 12.39% |
| 33 Year Change | -22.49% |
| 5 Year Change | n/a |
| Change since IPO | -35.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300497 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 7.6% | -1.9% | -1.2% |
| 1Y | 12.4% | -5.0% | 3.1% |
Return vs Industry: 300497 exceeded the CN Pharmaceuticals industry which returned -5% over the past year.
Return vs Market: 300497 exceeded the CN Market which returned 3.1% over the past year.
Price Volatility
| 300497 volatility | |
|---|---|
| 300497 Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 300497 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300497's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,963 | Jian Hua Bao | www.fushine.cn |
Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers penicillin, carbapenem, and other products, as well as intermediates of antiviral drugs. It also provides contract research, development, and manufacturing services, as well as engages in lithium battery electrolyte additives.
Jiangxi Fushine Pharmaceutical Co., Ltd. Fundamentals Summary
| 300497 fundamental statistics | |
|---|---|
| Market cap | CN¥6.65b |
| Earnings (TTM) | -CN¥181.24m |
| Revenue (TTM) | CN¥1.30b |
5.1x
P/S Ratio-36.7x
P/E RatioIs 300497 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300497 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.30b |
| Cost of Revenue | CN¥1.21b |
| Gross Profit | CN¥90.46m |
| Other Expenses | CN¥271.70m |
| Earnings | -CN¥181.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 6.96% |
| Net Profit Margin | -13.94% |
| Debt/Equity Ratio | 67.8% |
How did 300497 perform over the long term?
See historical performance and comparison